We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Nkarta Inc
2 own
2 watching
Current Price
$5.62
$-0.13
(-2.26%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
274.3M
52-Week High
20.35
52-Week Low
4.83
Average Volume
0.38M
Dividend Yield
--
P/E Ratio
--
Market Capitalization274.3M52-Week High20.3552-Week Low4.83Average Volume0.38MDividend Yield--P/E Ratio--What does the Nkarta Inc do?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More
How much money does Nkarta Inc make?
News & Events about Nkarta Inc.
Ticker Report
1month ago
Nkarta, Inc. (NASDAQ:NKTX Get Rating) has been given a consensus rating of Moderate Buy by the ten analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on ...
Globe Newswire
3 months ago
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy ...
Ticker Report
4 months ago
Nkarta, Inc. (NASDAQ:NKTX Get Rating) CEO Paul J. Hastings sold 6,126 shares of the firms stock in a transaction that occurred on Wednesday, September 21st. The stock was sold at an average price of $13.01, for a total transaction of $79,699.26. Following the completion of the ...
Market News Video
4 months ago
In trading on Monday, shares of Nkarta Inc (NKTX) crossed below their 200 day moving average of 12.95, changing hands as low as 12.60 per share. Nkarta Inc shares are currently trading off about 5% on the day...
Zolmax
9 months ago
Nkarta, Inc. (NASDAQ:NKTX Get Rating) shares gapped up before the market opened on Monday after Raymond James raised their price target on the stock from $17.00 to $32.00. The stock had previously closed at $7.77, but opened at $10.30. Raymond James currently has an outperform rating on the stock. ...
Frequently Asked Questions
Frequently Asked Questions
What is Nkarta Inc share price today?
Can Indians buy Nkarta Inc shares?
How can I buy Nkarta Inc shares from India?
Can Fractional shares of Nkarta Inc be purchased?
What are the documents required to start investing in Nkarta Inc stocks?
What is today’s traded volume of Nkarta Inc?
What is today’s market capitalisation of Nkarta Inc?
What is the 52-Week High and Low Range of Nkarta Inc?
What percentage is Nkarta Inc down from its 52-Week High?
What percentage is Nkarta Inc up from its 52-Week Low?
Current Price
$5.62
$-0.13
(-2.26%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.